It is reported that Zai Lab has recently submitted the F-1 document, which is going to be listed on the NASDAQ in the United States. The stock trading code is “ZLABâ€, raising US$115 million. Ding Ding Pharmaceutical was established in 2014. The legal representative YING DU has a registered capital of 66.5 million US dollars. The controlling shareholder Chuangchuang Pharmaceutical (Hong Kong) Co., Ltd. holds 100% of the shares. It is located in Shanghai Zhangjiang Hi-Tech Park and is dedicated to research, development and sales. Du Ying, chairman and CEO of the innovative pharmaceutical company, is a serial entrepreneur. She was responsible for the project acquisition and acquisition at the Pfizer headquarters in the United States. After returning to China, she founded Hutchison Whampoa Pharmaceuticals and then entered Sequoia Capital’s investment in healthcare . Later, he founded the Ding Ding Medicine. Previously, Ding Pharmaceutical completed a $30 million Series A financing in August 2014. The investors were Sequoia Capital and Qiming Venture Capital. In January 2016, it completed the B round of financing of USD 100 million, which was led by Shangyu Capital. Aobo Capital, Qiming Venture Capital, Sequoia Capital and Taifu Capital participated in the investment. In June 2017, it completed a $30 million Series C round of financing, led by Aobo Capital, and the company invested in Cormorant and Rock Springs Capital. Reed Pharmaceuticals has established a comprehensive product line mainly through internal R&D and licensing. Ding Ding has a management team with experience in global pharmaceutical companies and R&D institutions. This founder team has led several successful products to be recognized by China and the US Food and Drug Administration, and has tried and approved new drug rapid approval channels in China. It has also established long-term strategic partnerships with a number of multinational pharmaceutical giants. relationship. In March 2015, Bristol-Myers Squibb and Ding Ding Pharmaceutical signed a cooperation agreement to award the exclusive development, production and commercial promotion rights of Brinib in Greater China (Mainland and Hong Kong and Macao) to Ding Ding To obtain milestone payments for the drug at different stages of development and commercial profit sharing after listing. In November 2015, Ding Pharmaceutical and Korea and the United States reached a cooperation agreement on EGFR targeted lung cancer drug HM61713, and obtained its R&D, production and sales rights in China. In addition, Ding Ding has also cooperated with Sanofi in the development and marketization of two respiratory diseases. In terms of research and development, according to the CDE data, there are currently 10 drugs under research in Ding Ding Pharmaceutical, which are all Class 1 and Class 1.1 new drugs, including alanine Brinicib and ZL-2102. In the future, Ding Ding plans to establish a more complete drug discovery and development platform to introduce or internally develop more drugs to meet the needs of patients in China and the world. At the same time, the commercial team that Ding Pharmaceutical hopes to promote the products will also be gradually built. Diaphragm Valve,Stainless Steel Diaphragm Valve,Hygienic Diaphragm Valve,Stainless Steel Mix Valve Wenzhou Gaoya Light Industry Machinery Co.,ltd. , https://www.hongyafitting.com